Differential expression of HLA-A and B-alleles on uveal melanoma as determined by immuno-histology

Ocular Immunology and Inflammation

Volumn 4, Issue 1, 1996, Pages 1-14

  De Waard Siebinga, Itte ^a   Houbiers, Jos G A ^a   Hilders, Carina G J M ^a   De Wolff Rouendaal, Didi ^a   Jager, Martine J ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Allele specificity; HLA antigens; HLA expression; Tumor progression; Uveal melanoma

Indexed keywords

BETA 2 MICROGLOBULIN; HLA A ANTIGEN; HLA B ANTIGEN; MONOCLONAL ANTIBODY;

ADULT; AGED; ALLELE; ANTIGEN EXPRESSION; ANTIGEN PRESENTATION; ARTICLE; CLINICAL ARTICLE; FEMALE; HLA SYSTEM; HUMAN; HUMAN TISSUE; IMMUNOHISTOLOGY; IMMUNOPEROXIDASE STAINING; MALE; UVEA MELANOMA;

EID: 0030071433     PISSN: 09273948     EISSN: None     Source Type: Journal    
DOI: 10.3109/09273949609069122     Document Type: Article

References (49)

1. Zinkernagel RM, Doherty PC. MHC-restricted cytotoxic T-cells: studies on the biological role of polymorphic major transplantation antigens determining T-cell restriction-specificity, function, and responsiveness. Adv Immunol 1979; 27:51-77.
2. Benacerraf B. Role of MHC gene products in immune regulation. Science 1981; 212:1229-1238.
3. De Plaen E, Lurquin C, Van Pel A, Mariamé B, Szikora JP, Wölfel T, et al. Immunogenic (tum-) variants of mouse tumor P815: cloning of the gene of turn- antigen P91A and identification of the tum- mutation. Proc Natl Acad Sci USA 1988; 85:2274-2278.
4. Topalian SL. MHC class II restricted tumor antigens and the role of CD4+ T cells in cancer immunotherapy. Curr Opin Immunol 1994; 6:741-745.
5. Ostrand-Rosenberg S. Tumor immunotherapy: the tumor cell as an antigen-presenting cell. Curr Opin Immunol 1994; 6:722-727.
6. Melief CJM, Kast WM. Lessons from T cell responses to virus induced tumours for cancer eradication in general. Cancer Surv 1992; 13:81-99.
7. Festenstein H, Garrido F. MHC antigens and malignancy. Nature 1986; 322:502-503.
8. Cohen EP, Kim TS. Neoplastic cells that express low levels of MHC class I determinants escape host immunity. Semin Cancer Biol 1994; 5:419-428.
9. Garrido F, Ruiz-Cabello F. MHC expression on human tumors - its relevance for local tumor growth and metastasis. Semin Cancer Biol 1991; 2:3-10.
10. Natali PG, Nicotra MR, Bigotti A, Venturo I, Marcenaro L, Giacomini P, Russo C. Selective changes in expression of HLA-Class I polymorphic determinants in human solid tumors. Proc Natl Acad Sci USA 1989; 86:6719-6723.
11. López-Nevot MA, Esteban F, Ferrón A, Gutiérrez J, Oliva MR, Romero C, et al. HLA-Class I gene expression on human primary tumours and autologous metastasis: demonstration of selective losses of HLA antigens on colorectal, gastric and laryngeal carcinomas. Br J Cancer 1989; 59:221-226.
12. Kawakami Y, Zakut R, Topalian SL, Stötter H, Rosenberg SA. Shared human melanoma antigens: Recognition by tumor-infiltrating lymphocytes in HLA-A2.1-transfected melanomas. J Immunol 1992; 148:638-643.
13. Momburg F, Degener Th, Bacchus E, Moldenhauer G, Hämmerling GJ, Möller P. Loss of HLA-A,B,C and de novo expression of HLA-D in colorectal cancer. Int J Cancer 1986; 37:179-184.
14. Ruiter DJ, Bergman W, Welvaart K, Scheffer E, Van Vloten WA, Russo C, Ferrone S. Immunohistochemical analysis of malignant melanomas and nevocellular nevi with monoclonal antibodies to distinct monomorphic determinants of HLA antigens. Cancer Res 1984; 44:3930-3935.
15. Doherty PC, Knowles BB, Wettstein PJ. Immunological surveillance of tumors in the context of Major Histocompatibilty Complex restriction of T cell function. Adv Cancer Res 1984; 42:1-65.
16. Taramelli D, Fossati G, Balsari A, Marolda R, Parmiani G. The inhibition of lymphocyte stimulation by autologous human metastatic melanoma cells correlates with the expression of HLA-DR antigens on the tumor cells. Int J Cancer 1984; 34:797-806.
17. Jager MJ, De Wolff-Rouendaal D, Breebaart AC, Ruiter DJ. Expression of HLA antigens in paraffin sections of uveal melanomas. Doc Ophthalmol 1986; 64:69-76.
18. Jager MJ, Van der Pol JP, De Wolff-Rouendaal D, De Jong PTVM, Ruiter DJ. Decreased expression of HLA-Class II antigens on human uveal melanoma cells after in vivo X-ray irradiation. Am J Ophthalmol 1988; 105:78-86.
19. Natali PG, Bigotti A, Nicotra MR, Nardi RM, Delovu A, Segatto O, Ferrone S. Analysis of the antigenetic profile of uveal melanoma lesions with anti-cutaneous melanoma-associated antigen and anti-HLA monoclonal antibodies. Cancer Res 1989; 49:1269-1274.
20. Barnstable CJ, Bodmer WF, Brown G, Galfre G, Milstein C, Williams AF, Ziegler A. Production of monoclonal antibodies to group A erythrocytes, HLA and other human cell surface antigens. New tools for genetic analysis. Cell 1978; 14:9-20.
21. 2-microglobulin antibody and its use in the genetic and biochemical analysis of major histocompatibility antigens. Eur J Immunol 1979; 9:536-545.
22. Stam NJ, Spits H, Ploegh HL. Monoclonal antibodies raised against denaturated HLA-B locus heavy chains permit biochemical characterization of certain HLA-C locus products. J Immunol 1986; 137:2299-2306.
23. Stam NJ, Vroom ThM, Peters PJ, Pastoors EB, Ploegh HL. HLA-A-and HLA-B-specific monoclonal antibodies reactive with free heavy chains in Western blots, in formalin-fixed, paraffin-embedded tissue sections and in cryo-immuno-electron microscopy. Int Immunol 1990; 2:113-125.
24. Harpprecht J, Westphal E, Müller-Ruchholtz W. Production and applications of new monoclonal antibodies against human lymphocyte anti-A and -B antigens. Diagn Clin Immunol 1988; 5:8-388-392.
25. Parham P, Brodsky FM. Partial purification and some properties of BB7.2. Human Immunol 1981; 3:277-299.
26. McMichael AJ, Parham P, Rust N, Brodsky F. A monoclonal antibody that recognizes an antigenetic, determinant shared by HLA A2 and B17. Human Immunol 1980; 1:121-129.
27. Berger AE, Davis JE, Cresswell P. Monoclonal antibody to HLA-A3. Hybridoma 1982; 1(2); 87-90.
28. Radka SF, Kostyu DD, Amos DB. A monoclonal antibody directed against the HLABw6 epitope. J Immunol 1982; 128:2804-2806.
29. k cross-reacting with human DR molecule. I. Cross-inhibition studies of mAb cell surface fixation and differential binding of mAb to detergent-solubilized HLA molecules immobilized to a solid phase by a first mAb. Eur J Immunol 1983; 13:106-111.
30. Spits H, Borst J, Giphart M, Coligan J, Terhorst C, De Vries JE. HLA-DC antigens can serve as recognition elements for human cytotoxic T lymphocytes. Eur J Immunol 1984; 14:299-304.
31. Watson AJ, DeMars R, Trowbridge IS, Bach FH. Detection of a novel human Class II HLA antigen. Nature 1983; 304:358-361.
32. Creyghton WM, De Waard-Siebinga I, Danen EHJ, Luyten GPM, Van Muijen GNP, Jager MJ. Cytokine-mediated modulation of integrin, ICAM-1, nd CD44 expression on human uveal melanoma cells in vitro. Melanoma Research 1995; 235-242.
33. Boyum A. Separation of leucocytes from blood and bone marrow. Scand J Clin Lab Invest 1968; 21:77-89.
34. Terasaki PI, McClelland JD. A microdroplet assay of human serum cytotoxicity. Nature 1964; 204:998-1000.
35. Van Rood JJ. Leucocyte grouping. A method and its application. In: Thesis, Rijksuniversiteit Leiden. Den Haag: Pasmans, 1962; 1-58.
36. Ruiter DJ, Mattijssen V, Broecker EB, Ferrone S. MHC antigens in human melanomas. Semin Cancer Biol 1991; 2:35-45.
37. Lagaay AM, D'Amaro J, Lighthart GJ, Schreuder GMTh, Van Rood JJ, Hijmans W. Longevity and heredity in humans: Association with the human leucocyte antigen phenotype. Ann NY Acad Sci 1991; 621:78-89.
38. Bertrams J, Spitznas M, Rommelfanger M. Missing evidence for HLA antigen association with Eales' disease, chorioretinitis, central serous retinopathy, and malignant choroidal melanoma. Invest Ophthalmol Vis Sci 1978; 17:918-920.
39. Völker-Dieben HJM, D'Amaro J, De Lange P, De Wolff-Rouendaal D. HLA and ABO antigens in patients with malignant choroidal melanoma. Clin Exp Immunol 1983; 53:581-588.
40. Smith MEF. MHC antigen expression in colorectal tumours. Semin Cancer Biol 1991; 2:17-21.
41. Connor ME, Stern PL. Loss of MHC Class-I expression in cervical carcinomas. Int. J Cancer 1990; 46:1029-1934.
42. Kaklamanis L, Hill A. MHC loss in colorectal tumours: Evidence for immunoselection? Cancer Surv 1992; 13:155-171.
43. Ksander BR, Rubsamen PE, Olsen KR, Cousins SW, Streilein JW. Studies of tumor infiltrating lymphocytes from a human choroidal melanoma. Invest Ophthalmol Vis Sci 1991; 32:3198-3208.
44. Ma D, Luyten G, Luider ThM, Niederkorn JY. Relationship between natural killer cell susceptibility and metastasis of human uveal melanoma cells in a murine model. Invest Ophthalmol Vis Sci 1995; 36:435-441.
45. Versteeg R, Kruse-Wolters M, Plomp AC, Van Leeuwen A, Stam NJ, Ploegh HL, Ruiter DJ, Schrier PI. Suppression of Class I human histocompatibility leucocyte antigen by c-myc is locus specific. J Exp Med 1989; 170:621-635.
46. 2-microglobulin messenger RNA. J Clin Invest 1993; 91:684-692.
47. Marincola FM, Shamamian P, Alexander RB, Gnarra JR, Turetskaya RL, Nedospasov SA, et al. Loss of haplotype and B locus down-regulation in melanoma cell lines. J Immunol 1994; 153:1225-1237.
48. Crowly NJ, Darrovv TL, Quin-Allen MA, Seigler HF. MHC-related recognition of autologous melanoma by tumorspecific cytotoxin T cells - Evidence for restriction by a dominant HLA-Aallele. J Immunol 1991; 146:1692-1699.
49. Pardoll DM. Cancer vaccines. Immunol Today 1993; 14:310-316.